Bimzelx (bimekizumab-bkzx)
Condition : New
0
From UAE
To United States
in 5-10 days
Description
Bimzelx (bimekizumab) is a monoclonal antibody used for treating moderate to severe plaque psoriasis in adults. It works by selectively binding and neutralizing interleukin-17A and interleukin-17F (IL-17A and IL-17F), which are cytokines involved in inflammatory processes.
Mechanism of Action:
Bimzelx blocks the activity of IL-17A and IL-17F cytokines, preventing them from interacting with their receptors, which are crucial in driving inflammation in skin conditions like psoriasis.Indications:
Bimzelx is primarily indicated for:- Moderate to severe plaque psoriasis in adults, especially when other systemic therapies are inadequate.
Side Effects:
Common side effects of Bimzelx include:- Upper respiratory infections
- Oral candidiasis (fungal infection in the mouth)
- Injection site reactions
- Headache
- Herpes simplex infections
- Gastroenteritis
- Tinea infections (fungal)
Contraindications:
Bimzelx should not be used in the following conditions:- Active infections: Patients with untreated tuberculosis or other serious infections should avoid this treatment.
- Hypersensitivity: Anyone with known allergies to bimekizumab or its excipients.
- Severe depression or suicidal ideation: Use with caution in patients with a history of depression
Global Prices:
Bimzelx (Bimekizumab) Prices in Different Countries
Country | Price (per injection) | Source |
---|---|---|
USA | $13,000 | Drugs.com |
UK | £9,500 | NHS |
Germany | €12,000 | MIMS Germany |
Canada | CAD 16,000 | Health Canada |
Australia | AUD 18,000 | PBS Australia |